I worry about really long term use and atypical fractures Irwin, pretty serious consideration after 7 years of BP therapy. https://t.co/RUQeLbpZjm

• Dr Irwin Lim on Twitter: "Straw poll: how many of you typically cease oral…

@_connectedcare @LaurentGrange I am just curious to see their names but really challenging to remember them. https://t.co/TuKQNcfu5m

Gout and associated comorbidities - Edward Roddy @KeeleUniversity #EULAR2019 https://t.co/KC3ITm0FKZ

Multitarget therapy for #Lupus under development 👉🏻 Fenebrutinib @Roche 👉🏻 Evobrutinib @MerckHealthcare 👉🏻 Spleen Kinase Inhibitors @GileadSciences @RigelPharma 👉🏻 Encoding transcription factors @Celgene 👉🏻 JAK/Tyk Inhibitors @PfizerCongress @LillyRheumEU @bmsnews @GSK #EULAR2019 https://t.co/CeUwIQaCx4

Gout management in CKD & allopurinol in the renal function.. - Roddy @KeeleUniversity #EULAR2019 https://t.co/B9TP4jHb4k

https://t.co/qglhyTfYvG

• Suleman Khan FRCP was live

Marc de Meulemeester presents finding of #gout survey of 1100 patients across Europe at #EULAR2019. Significant burden of disease: 10% of patients had lost their job/retired due to gout, ability to walk, sleep, mental health & sex lives affected. https://t.co/uAcoChIBhV

Ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic #lupus erythematosus - a between group difference of 29%. Article in @TheLancet https://t.co/kic3xAfHcE #EULAR2019 #LancetRheumatology https://t.co/Wizel4nnSk

• DEFINE_ME

Predictors of severe cranial ischemic complications in Giant cell arteritis. 20%GPC patients presented/developed severe vision manifestations and/or ischemic stroke.. age and jaw claudication predicted severe cranial ischemic complications ~ Alojzija Hocevar #eular2019 https://t.co/PSaRfD5kSa

GIACTA update #eular2019 RT @drdavidliew: To recall, part 1 52 wks, TCZ vs placebo & wean prednisolone. By end 52 wks, defined themselves by their response categories: remission no treatment, remission on treatment, active on treatment. What happens when IL-6 inhibition stops?

IL-17A and IL-17F are secreted by entheseal T cells, and both synergize with TNF to recruit IL-17+ T cells to sites of inflammation. Timely translational data for bimekizumab #EULAR2019 THU0013 from Dennis McGonagle’s Leeds group @RheumNow https://t.co/27DMCBj1VV

#Comorditiy is common in #gout & distinct #clusters form. #allopurinol can be safely be used in #ckd at higher than historically suggested doses. Uncertainty remains around association between gout & #neurodegeneration. #EULAR2019 @GoutEducation @GoutandYou @PCSciences @elinlowri https://t.co/7z6ZkbnZRZ

Lots of interesting questions posed by Dr. Eckstein #EULAR2019 here’s the FDA draft guidelines on structural endpoints in DMOAd development: https://t.co/mAKpASXXDb https://t.co/xAncVGyZjn

• Osteoarthritis: Structural Endpoints for the Development of Drugs | FDA

GM-CSF may be implicated in many pathways in GCA, and its genetic signature in fresh temporal arteries is markedly increased in GCA vs controls. The anti-GM-CSF mAbs for GCA - watch this space #EULAR2019 THU0008 by Maria Cid @RheumNow https://t.co/smStOBq17b

Comorbidity is common in gout, is challenging in CKD, allopurinol can be safely dosed higher than historical, uncertainty about relationships between urate gout and neurodegeneration .. avoid <3mg/dl in long term.. Dr. Roddy UK @KeeleUniversity #EULAR2019 https://t.co/TvESMxHG6y